Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The High-affinity immunoglobulin epsilon receptor subunit gamma (FcRγ) is a critical transmembrane adapter protein that functions as the signaling module for several important immune and platelet receptors, including the high-affinity IgE receptor (FcεRI), various IgG receptors (FcγRI, FcγRIII), and the platelet collagen receptor Glycoprotein VI (GPVI) [1, 2]. It is characterized by the presence of an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, which is essential for initiating intracellular signaling upon ligand binding to the associated receptor [3]. When the extracellular receptor is engaged, the ITAM in the FcRγ chain is phosphorylated by Src-family kinases, creating docking sites for the Syk tyrosine kinase, which then triggers downstream pathways such as the PLCγ and MAPK cascades [3, 4]. These pathways drive essential cellular processes including mast cell degranulation, antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and platelet aggregation [1, 4]. Given its central role in both allergic inflammation and arterial thrombosis, FcRγ and its signaling components are significant targets for therapeutic development in conditions like asthma, rheumatoid arthritis, and cardiovascular disease [5, 6]. While direct inhibitors of the gamma chain itself are not currently in clinical use, the pathway is effectively targeted through the inhibition of its associated receptors or the downstream kinase Syk [5, 7].
The mechanism of action for drugs targeting the Fc receptor gamma chain pathway involves the disruption of ITAM-mediated signaling. This is typically achieved by either blocking the extracellular receptors that require the gamma chain for signal transduction, such as GPVI or Fc receptors, or by inhibiting the downstream tyrosine kinase Syk, which binds to the phosphorylated ITAM of the gamma chain to initiate the intracellular signaling cascade [3, 5, 6].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High-affinity immunoglobulin epsilon receptor subunit gamma (FcRγ) (FcRγ).